Dr David A Kingrey, MD | |
1100 N Topeka St, Wichita, KS 67214-2810 | |
(316) 263-6273 | |
(316) 263-5568 |
Full Name | Dr David A Kingrey |
---|---|
Gender | Male |
Speciality | Ophthalmology |
Experience | 30 Years |
Location | 1100 N Topeka St, Wichita, Kansas |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1093781593 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207W00000X | Ophthalmology | 0427242 (Kansas) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Vision Surgery Consultants Pa | 2062454622 | 4 |
News Archive
Scientists have identified the virus likely to have caused a pneumonia-like illness that has caused an outbreak in Wuhan, China.
NexBio, Inc. announced today the initiation of a trial of DAS181 (FludaseĀ®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Allergan plc., a leading global pharmaceutical company today announced that its Phase III ready investigational medication rapastinel (GLYX-13) received Breakthrough Therapy designation from the U.S. Food and Drug Administration for adjunctive treatment of Major Depressive Disorder (MDD).
Scientists at the UNC School of Medicine have reported in the journal JCI Insight encouraging early tests of a gene therapy strategy against Angelman syndrome, a neurodevelopmental disorder that features poor muscle control and balance, hard-to-treat epilepsy, and intellectual disabilities.
› Verified 6 days ago
Entity Name | Vision Surgery Consultants Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1922104470 PECOS PAC ID: 2062454622 Enrollment ID: O20100526000491 |
News Archive
Scientists have identified the virus likely to have caused a pneumonia-like illness that has caused an outbreak in Wuhan, China.
NexBio, Inc. announced today the initiation of a trial of DAS181 (FludaseĀ®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Allergan plc., a leading global pharmaceutical company today announced that its Phase III ready investigational medication rapastinel (GLYX-13) received Breakthrough Therapy designation from the U.S. Food and Drug Administration for adjunctive treatment of Major Depressive Disorder (MDD).
Scientists at the UNC School of Medicine have reported in the journal JCI Insight encouraging early tests of a gene therapy strategy against Angelman syndrome, a neurodevelopmental disorder that features poor muscle control and balance, hard-to-treat epilepsy, and intellectual disabilities.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Dr David A Kingrey, MD 1100 N Topeka St, Wichita, KS 67214-2810 Ph: (316) 263-6273 | Dr David A Kingrey, MD 1100 N Topeka St, Wichita, KS 67214-2810 Ph: (316) 263-6273 |
News Archive
Scientists have identified the virus likely to have caused a pneumonia-like illness that has caused an outbreak in Wuhan, China.
NexBio, Inc. announced today the initiation of a trial of DAS181 (FludaseĀ®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Allergan plc., a leading global pharmaceutical company today announced that its Phase III ready investigational medication rapastinel (GLYX-13) received Breakthrough Therapy designation from the U.S. Food and Drug Administration for adjunctive treatment of Major Depressive Disorder (MDD).
Scientists at the UNC School of Medicine have reported in the journal JCI Insight encouraging early tests of a gene therapy strategy against Angelman syndrome, a neurodevelopmental disorder that features poor muscle control and balance, hard-to-treat epilepsy, and intellectual disabilities.
› Verified 6 days ago
David M Kahn, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 818 N Carriage Pkwy, Wichita, KS 67208 Phone: 316-651-2300 Fax: 316-651-2358 | |
Dasa V Gangadhar, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 655 N Woodlawn, Wichita, KS 67206 Phone: 316-684-5158 Fax: 316-681-1005 | |
C Eric Shrader, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 655 N Woodlawn, Wichita, KS 67208 Phone: 316-684-5158 Fax: 316-858-3830 | |
Dr. Anita Campbell, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1277 N Maize Rd, Wichita, KS 67212 Phone: 316-722-8883 Fax: 316-609-4740 | |
Michael S Bolt, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 834 N Socora, Ste 2, Wichita, KS 67212 Phone: 316-722-8883 Fax: 316-721-4864 | |
Terria L Winn, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 834 N Socora St, Wichita, KS 67212 Phone: 316-722-8883 Fax: 316-721-4864 |